Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
29.89
+0.59 (2.01%)
At close: Oct 9, 2026, 4:00 PM EDT
30.00
+0.11 (0.37%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Celldex Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Celldex Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $63.07. The average 1-year stock price forecast is 111.01% higher than the current stock price, while the lowest is $28 (-6.32%) and the highest is $100 (+234.56%).
Price Target: $63.07 (+111.01%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 13 | 13 | 13 | 12 | 12 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 16 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $38 → $28 | Hold | Maintains | $38 → $28 | -6.32% | Oct 5, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $56 → $64 | Buy | Maintains | $56 → $64 | +114.12% | Oct 3, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $64 | Buy | Maintains | $64 | +114.12% | Oct 2, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $70 → $88 | Buy | Reiterates | $70 → $88 | +194.41% | Sep 23, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $100 | Buy | Reiterates | $100 | +234.56% | Sep 23, 2026 |
Financial Forecast
Revenue This Year
1.85M
from 1.55M
Increased by 19.74%
Revenue Next Year
9.95M
from 1.85M
Increased by 438.11%
EPS This Year
-4.12
from -3.90
EPS Next Year
-4.24
from -4.12
EPS and Forward PE are based on non-GAAP adjusted numbers.